FDA Removes Warning On Hikma Pharmaceuticals Facility

News: The US Food and Drug Administration (FDA) has removed the warning issued to Jordon-based drugmaker Hikma Pharmaceuticals on its Eatontown facility in New Jersey, the US. The company produces oral pharmaceutical products for the US market at the Eatontown facility. The FDA made the move after the company successfully resolved all issues raised by the US regulator regarding the facility in February 2012, according to the company. Hikma Pharmaceuticals' CEO Said Darwazah said: 'The company is pleased to report that it has brought Eatontown facility back into compliance with US FDA', reports Reuters. The company plans to gradually reintroduce pharmaceutical products produced at the facility to the US market.

This article is tagged to:
Related sectors of this article: Pharmaceuticals & Healthcare, Regulatory - Pharmaceuticals & Healthcare
Geography: United States

Enter your details to read the full article

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.